JCRB1032 OZ
細胞情報
Important Notice(s)On the agreement for distribution of JHH series cell lines, NOZ and OZ
細胞種類：一般細胞 (細胞分譲手数料はこちら)
| 細胞番号(JCRB) | JCRB1032 | 細胞名 | OZ |
|---|---|---|---|
| 生物種(日本語) | ヒト | 組織名(日本語) | 肝臓, 胆嚢 |
| コメント(日本語) | 胆管がん | プロフィール | Human bile duct cell line established from ascites of the tumor patient who had differentiated adenocarcinoma. |
| 別名 | 動物名 | human | |
| 系統名 | 学名・属名 | Homo | |
| 種名 | sapiens | 性別 | M |
| 年齢・月齢 | 71 | 細胞識別情報 | available |
| （癌）原発組織名 | liver, gallbladder | 病歴情報 | differentiated adenocarcinoma papilla and poorly differentiated adenocarcinoma. CEA 8.0 ng/ml. |
| 転移の有無（Y/N） | Yes | （癌）転移組織名 | ascites |
| 遺伝的性質 | No. of chromosome, 51. Td=48 hrs. | 細胞寿命 | infinite |
| ｸﾗｲｼｽＰＤＬ | 形態 | epithelial-like | |
| 一般性状 | Cells were established from ascites of the patient whose bile duct was emphraxed by mucinous materials produced by adenocarcinoma cells. Cells produce CEA, BMG. High levels of P1-P, r-GTP, LDH were observed in cells. PAS (+). Transplantalbe to nude mice. | 細胞分類 | tumor |
| 細胞樹立者名 | Honma,S. & Nagamori,S. | 細胞寄託者 | Nagamori,S. |
| 分譲時制限 | Require negotiation and agreement from Dr.Nagamori before shipping. | コメント | Cell Bank will handle to get the approval but the depositor may contact to the requested person directly. (r-GPT = gamma GPT) |
| 入手年 | 2001 | 培養培地 | Williams'E medium with 10% fetal calf serum. |
| 継代方法 | Cells are harvested after treatment with 0.25% trypsin and 0.02% EDTA. | 継代時細胞数 | |
| 人種 | Japanese | 炭酸ガス濃度 | 5 % |
| 採取組織名 | ascites | 組織型 |
| ウイルスDNA・RNA検出検査 (Detection of virus genome fragment by Real-time PCR) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ウイルスDNA 検出検査 |
tested | ウイルスRNA 検出検査 |
tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:2889643 | Human bile duct carcinoma cell line producing abundant mucin in vitro. Homma S,Nagamori S,Fujise K,Yamazaki K,Hasumura S,Sujino H,Matsuura T,Shimizu K,Kameda H,Takaki K Gastroenterol Jpn. 1987 Aug;22(4):474-9 |
| Research results by users. Click！ | |
|---|---|
| Pubmed id:23084587 |
Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma. Ryu HS,Chung JH,Lee K,Shin E,Jing J,Choe G,Kim H,Xu X,Lee HE,Kim DG,Lee H,Jang JJ Hum Pathol. 2012 Dec;43(12):2360-70 |
| Pubmed id:22639408 |
Twisted gastrulation expression in cholangiocellular and hepatocellular carcinoma. Johnston J,Al-Bahrani R,Abuetabh Y,Chiu B,Forsman CL,Nagamori S,Leng R,Petryk A,Sergi C J Clin Pathol. 2012 Oct;65(10):945-8 |
| Pubmed id:22457476 |
Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Moldenhauer G,Salnikov AV,Lüttgau S,Herr I,Anderl J,Faulstich H J Natl Cancer Inst. 2012 Apr 18;104(8):622-34 |
| Pubmed id:22309595 |
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. Miura S,Mitsuhashi N,Shimizu H,Kimura F,Yoshidome H,Otsuka M,Kato A,Shida T,Okamura D,Miyazaki M BMC Cancer. 2012 Feb 6;12():56 |
| Pubmed id:22075503 |
Expression of E-cadherin and β-catenin in two cholangiocarcinoma cell lines (OZ and HuCCT1) with different degree of invasiveness of the primary tumor. Abuetabh Y,Persad S,Nagamori S,Huggins J,Al-Bahrani R,Sergi C Ann Clin Lab Sci. 2011 Summer;41(3):217-23 |
| Pubmed id:20922056 |
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. Yu L,Feng M,Kim H,Phung Y,Kleiner DE,Gores GJ,Qian M,Wang XW,Ho M J Cancer. 2010 Oct 1;1():141-9 |
| Pubmed id:20565817 |
Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. Xu L,Hausmann M,Dietmaier W,Kellermeier S,Pesch T,Stieber-Gunckel M,Lippert E,Klebl F,Rogler G BMC Cancer. 2010 Jun 18;10():302 |
| Pubmed id:20044606 |
Infrequent amplification of JUN in hepatocellular carcinoma. Endo M,Yasui K,Nakajima T,Gen Y,Tsuji K,Dohi O,Zen K,Mitsuyoshi H,Minami M,Itoh Y,Taniwaki M,Tanaka S,Arii S,Okanoue T,Yoshikawa T Anticancer Res. 2009 Dec;29(12):4989-94 |
| Pubmed id:19319137 |
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Yoshikawa D,Ojima H,Kokubu A,Ochiya T,Kasai S,Hirohashi S,Shibata T Br J Cancer. 2009 Apr 21;100(8):1257-66 |
| Pubmed id:19453019 |
Rapamycin inhibits growth of cholangiocarcinoma cells. Okada T,Sawada T,Kubota K Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10 |
| Pubmed id:19383345 |
Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Ueda N,Shiraha H,Fujikawa T,Takaoka N,Nakanishi Y,Suzuki M,Matsuo N,Tanaka S,Nishina S,Uemura M,Takaki A,Shiratori Y,Yamamoto K Mol Oncol. 2008 Oct;2(3):241-9 |
| Pubmed id:18442209 |
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. Xu LN,Wang X,Zou SQ World J Gastroenterol. 2008 Apr 28;14(16):2578-81 |
| Pubmed id:15492814 |
Anti-endostatin monoclonal antibody enhances growth of human hepatocellular carcinoma cells by inhibiting activity of endostatin secreted by the transplanted cells in nude mice. Tsuboi S,Nouso K,Tomono Y,Nagamori S,Naito I,Watanabe T,Manabe K,Ohmori H,Nakatsukasa H,Miyazaki M,Higashi T,Shiratori Y,Namba M,Ninomiya Y Int J Oncol. 2004 Nov;25(5):1267-71 |
| Pubmed id:12654561 |
Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement. Nagi P,Vickers SM,Davydova J,Adachi Y,Takayama K,Barker S,Krasnykh V,Curiel DT,Yamamoto M J Gastrointest Surg. 2003 Mar-Apr;7(3):364-71 |
| Pubmed id:9446792 |
Cyclin E overexpression responsible for growth of human hepatic tumors with p21WAF1/CIP1/SDI1. Tsuji T,Miyazaki M,Fushimi K,Mihara K,Inoue Y,Ohashi R,Ohtsubo M,Hamazaki K,Furusako S,Namba M Biochem Biophys Res Commun. 1998 Jan 14;242(2):317-21 |
| Pubmed id:9135018 |
Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Sampson LK,Vickers SM,Ying W,Phillips JO Cancer Res. 1997 May 1;57(9):1743-9 |
| Pubmed id:8835345 |
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines. Tsuboi S,Nagamori S,Miyazaki M,Mihara K,Fukaya K,Teruya K,Kosaka T,Tsuji T,Namba M J Med Virol. 1996 Feb;48(2):133-40 |
| Pubmed id:1701409 |
Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Fujise K,Nagamori S,Hasumura S,Homma S,Sujino H,Matsuura T,Shimizu K,Niiya M,Kameda H,Fujita K Hepatogastroenterology. 1990 Oct;37(5):457-60 |
| Pubmed id:2889643 |
Human bile duct carcinoma cell line producing abundant mucin in vitro. Homma S,Nagamori S,Fujise K,Yamazaki K,Hasumura S,Sujino H,Matsuura T,Shimizu K,Kameda H,Takaki K Gastroenterol Jpn. 1987 Aug;22(4):474-9 |
| Pubmed id:3005723 |
[Effects of hyperthermia on the proliferation and viability of cultured human hepatobiliary carcinoma cells]. Homma S,Nagamori S,Fujise K,Sujino H,Matsuura T,Simizu K,Kameda H Nihon Shokakibyo Gakkai Zasshi. 1985 Sep;82(9):2043-8 |
| Pubmed id:none |
高分化型ヒト不死化肝細胞株(OUMS‐29)と肝癌細胞株(JHH‐1)でのエンドスタチン分泌の相違 友野靖子 安藤香織 内藤一郎 佐渡義一 坪井壮 永森静志 宮崎正博 沖垣達 二宮善文 重井医学年報 24, 7-14 (2003) |
| Pubmed id:none |
樹立ヒト肝癌株細胞中のB型肝炎ウイルスゲノム 藤瀬 清隆, 藤多 和信, 永森 静志, 蓮村 哲, 本間 定, 筋野 甫, 松浦 知和, 清水 恵一郎, 新谷 稔, 大野 典也, 亀田 治男 肝臓 29(5), 697-698 (1988) |
| Pubmed id:none |
ヒト肝胆道系癌培養細胞の生存と増殖に及ぼす温熱の効果 本間 定, 永森 静志, 藤瀬 清隆, 筋野 甫, 松浦 知和, 清水 恵一郎, 亀田 治男 肝臓 24(5), 569 (1983) |
| Images |
|---|
                    |
| Movies |
|---|
|
LOT Information
| 細胞番号 | JCRB1032 | 細胞名 | |
|---|---|---|---|
| 培養ロット番号 | 05222012 | 培養種別 | distribution |
| 培地 | Williams' E medium with 10% fetal bovine serum (FBS, GIBCO Cat. # 10099) | 培養温度 | 37 C |
| 継代時細胞数（濃度） | 1 - 3 x 10^5 cells/mL | 継代方法 | Cells were harvested after treatment with 0.25% trypsin and 0.02% EDTA. |
| 増殖速度 | 3 - 4 days | 凍結時生細胞濃度 | 2.0 x 10^6 |
| 凍結時生細胞率 | 93.0 | 使用抗生物質 | free |
| 継代数 | Unknown (16 at bank) | PDL数（プライマリ） | |
| ﾏｲｺﾌﾟﾗｽﾞﾏ検出 | - | 細菌汚染検出 | - |
| 真菌汚染検出 | - | ｱｲｿｻﾞｲﾑ検査・動物名 | Confirmed as human by NP, G6PD (type B), MD. |
| 染色体モード | 染色体情報 | ||
| 表面抗原 | DNA Profile (STR) | ||
| 接着性 | Yes | 導入外部遺伝子 | |
| 凍結培地 | 10% DMSO, 20% FBS - Williams' E | 炭酸ガス濃度 | 5% |
| 解凍後生細胞率 | 追加情報 |
| 細胞番号 | JCRB1032 | 細胞名 | |
|---|---|---|---|
| 培養ロット番号 | 03192007 | 培養種別 | distribution |
| 培地 | William's E medium with 10% fetal bovine serum (FBS lot; GIBCO 484375) | 培養温度 | 37 C |
| 継代時細胞数（濃度） | approx. 1 x 10^5 cells/ml | 継代方法 | 0.25% trypsin and 0.02% EDTA, passage once a week. Cells attached hard to dishes and trypsinization at 37 C for 20-30 minutes required. |
| 増殖速度 | 80 hrs | 凍結時生細胞濃度 | 1.8 x 10^6 |
| 凍結時生細胞率 | 98.3 | 使用抗生物質 | free |
| 継代数 | Unknown (9 at bank) | PDL数（プライマリ） | |
| ﾏｲｺﾌﾟﾗｽﾞﾏ検出 | - | 細菌汚染検出 | - |
| 真菌汚染検出 | - | ｱｲｿｻﾞｲﾑ検査・動物名 | Confirmed as human by NP and G6PD, LD, MD. |
| 染色体モード | 染色体情報 | ||
| 表面抗原 | DNA Profile (STR) | ||
| 接着性 | Yes | 導入外部遺伝子 | |
| 凍結培地 | 10% DMSO, 20% FBS - William's E medium | 炭酸ガス濃度 | 5% |
| 解凍後生細胞率 | 追加情報 |
| 細胞番号 | JCRB1032 | 細胞名 | OZ |
|---|---|---|---|
| 培養ロット番号 | 02212003 | 培養種別 | distribution |
| 培地 | Williams'E medium with 10% fetal calf serum(Intergen RB52305). | 培養温度 | 37 C |
| 継代時細胞数（濃度） | 1.2 x 10^4 cells/sq.cm. | 継代方法 | Cells were harvested after treatment with 0.2% trypsin. Medium change twice a week and subculture every 10 days.. |
| 増殖速度 | NT | 凍結時生細胞濃度 | 1.4 x 10^6 |
| 凍結時生細胞率 | 96.1 | 使用抗生物質 | free |
| 継代数 | P6* | PDL数（プライマリ） | NT |
| ﾏｲｺﾌﾟﾗｽﾞﾏ検出 | - | 細菌汚染検出 | - |
| 真菌汚染検出 | - | ｱｲｿｻﾞｲﾑ検査・動物名 | G6PD(not shown), NP, LDH examined. Human. |
| 染色体モード | NT | 染色体情報 | NT |
| 表面抗原 | NT | DNA Profile (STR) | |
| 接着性 | Yes | 導入外部遺伝子 | NT |
| 凍結培地 | Culture medium with 5% DMSO. | 炭酸ガス濃度 | 5 % |
| 解凍後生細胞率 | NT | 追加情報 |
| Images |
|---|
|
|
| 細胞番号 | JCRB1032 | 細胞名 | OZ |
|---|---|---|---|
| 培養ロット番号 | 12092020 | 培養種別 | distribution |
| 培地 | Williams' E medium with 10% fetal bovine serum (FBS, Sigma Cat. # 172012, Lot 12J396) | 培養温度 | 37 C |
| 継代時細胞数（濃度） | 3.6 - 5.4 x 10^4 cells/mL | 継代方法 | Cells were harvested after treatment with 0.2% trypsin. |
| 増殖速度 | approx. 44 hrs. | 凍結時生細胞濃度 | 6.1 x 10^5 |
| 凍結時生細胞率 | 96 | 使用抗生物質 | free |
| 継代数 | Unknown (10 at bank) | PDL数（プライマリ） | |
| ﾏｲｺﾌﾟﾗｽﾞﾏ検出 | - | 細菌汚染検出 | - |
| 真菌汚染検出 | - | ｱｲｿｻﾞｲﾑ検査・動物名 | |
| 染色体モード | 染色体情報 | ||
| 表面抗原 | DNA Profile (STR) | ||
| 接着性 | Yes | 導入外部遺伝子 | |
| 凍結培地 | 10% DMSO, 20% FBS - Williams' E | 炭酸ガス濃度 | 5% |
| 解凍後生細胞率 | 76 | 追加情報 |